We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+13.69%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$53.1B
AUM Growth
+$6.76B
(+15%)
Cap. Flow
+$2.33B
Cap. Flow
% of AUM
4.39%
Top 10 Holdings %
Top 10 Hldgs %
14.65%
Holding
2,220
New
169
Increased
729
Reduced
1,033
Closed
165
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zscaler
ZS
|
+$222M |
| 2 |
Palantir
PLTR
|
+$221M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$213M |
| 4 |
FirstEnergy
FE
|
+$189M |
| 5 |
Broadcom
AVGO
|
+$174M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$383M |
| 2 |
Philip Morris
PM
|
+$280M |
| 3 |
Entergy
ETR
|
+$207M |
| 4 |
Paychex
PAYX
|
+$206M |
| 5 |
Gilead Sciences
GILD
|
+$201M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.81% |
| 2 | Healthcare | 14.57% |
| 3 | Financials | 13.43% |
| 4 | Industrials | 10.29% |
| 5 | Consumer Discretionary | 9.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1126
ASE Group
ASX
$98.4B
| $1.08M | ﹤0.01% |
104,136
| – | – |
|
1127
Medifast
MED
$136M
| $1.08M | ﹤0.01% |
76,549
-99,221
| -56% | -$1.3M |
|
1128
American Homes 4 Rent
AMH
$12.1B
| $1.07M | ﹤0.01% |
29,728
-373
| -1% | -$13.8K |
|
1129
Annaly Capital Management
NLY
$17.4B
| $1.06M | ﹤0.01% |
56,486
+7,748
| +16% | +$147K |
|
1130
Toll Brothers
TOL
$13.5B
| $1.06M | ﹤0.01% |
9,283
-176
| -2% | -$18.3K |
|
1131
Visteon
VC
$2.72B
| $1.06M | ﹤0.01% |
11,352
-21,303
| -65% | -$1.75M |
|
1132
Vicor
VICR
$8.66B
| $1.06M | ﹤0.01% |
23,329
-91,936
| -80% | -$4.11M |
|
1133
Criteo S.A.
CRTO
$855M
| $1.06M | ﹤0.01% |
44,059
-46,362
| -51% | -$1.31M |
|
1134
Dolby
DLB
$5.76B
| $1.05M | ﹤0.01% |
14,133
-11,962
| -46% | -$895K |
|
1135
Vestis
VSTS
$1.65B
| $1.05M | ﹤0.01% |
183,038
+61,449
| +51% | +$431K |
|
1136
Stride
LRN
$3.61B
| $1.05M | ﹤0.01% |
7,218
-76
| -1% | -$11K |
|
1137
Biomea Fusion
BMEA
$125M
| $1.04M | ﹤0.01% |
576,364
-17,757
| -3% | -$34.2K |
|
1138
Aramark
ARMK
$15.3B
| $1.02M | ﹤0.01% |
24,465
-638
| -3% | -$23.7K |
|
1139
EnerSys
ENS
$6.69B
| $1.02M | ﹤0.01% |
11,935
-21,860
| -65% | -$1.91M |
|
1140
Carlyle Group
CG
$17.5B
| $1.02M | ﹤0.01% |
19,891
-92
| -0.5% | -$3.96K |
|
1141
Rackspace Technology
RXT
$803M
| $1.02M | ﹤0.01% |
795,067
+609
| +0.1% | +$793 |
|
|
AVB
1142
DELISTED
AvalonBay Communities
AVB
| $1.01M | ﹤0.01% |
4,961
-1,376
| -22% | -$281K |
|
1143
Occidental Petroleum
OXY
$59.1B
| $1.01M | ﹤0.01% |
23,997
+20,985
| +697% | +$877K |
|
1144
Ally Financial
ALLY
$12.8B
| $1.01M | ﹤0.01% |
25,853
-2,105
| -8% | -$72.9K |
|
1145
Alerus Financial
ALRS
$825M
| $1.01M | ﹤0.01% |
46,461
-536
| -1% | -$10.7K |
|
1146
Chewy
CHWY
$9.52B
| $1.01M | ﹤0.01% |
23,589
+7,904
| +50% | +$315K |
|
1147
Alliant Energy
LNT
$17.6B
| $989K | ﹤0.01% |
16,350
-11,326
| -41% | -$693K |
|
1148
HealthEquity
HQY
$7.97B
| $983K | ﹤0.01% |
9,383
-373
| -4% | -$35.4K |
|
1149
Cal-Maine
CALM
$3.75B
| $958K | ﹤0.01% |
9,615
+9,594
| +45,686% | +$917K |
|
1150
MACOM Technology Solutions
MTSI
$20.3B
| $957K | ﹤0.01% |
6,676
-163
| -2% | -$19K |
|
Similar funds
Federated Hermes's Q2 2025 Portfolio in Review
As of Q2 2025, Federated Hermes held 2,220 positions worth $53.1B, up 15% from $46.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Federated Hermes deployed $2.33B of net new capital in Q2 2025, opening 169 new positions and adding to 729 existing holdings. Its largest new stake was Genuine Parts: 882,160 shares worth $107M.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 20% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $383M trimmed.
- Federated Hermes's largest Q2 2025 buy was Genuine Parts: 882,160 shares worth $107M.
- Federated Hermes added most to Zscaler in Q2 2025, an estimated $222M increase.
- Federated Hermes's biggest Q2 2025 reduction was Bristol-Myers Squibb, cutting an estimated $383M.
- Federated Hermes fully exited Regulus Therapeutics in Q2 2025, selling an estimated $39.2M.
- Federated Hermes's ten largest holdings make up 15% of its $53.1B portfolio in Q2 2025.
- Federated Hermes opened 169 new positions and closed 165 in Q2 2025.
- Federated Hermes's portfolio value rose 15% quarter-over-quarter to $53.1B.
Based on Federated Hermes's 13F filing for Q2 2025, filed 13 Aug 2025.